Cited by 195Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsHeart Failure Treatment and Management

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

Open access

Sheahan, Kelsey H, Wahlberg, Elizabeth A, Gilbert, Matthew P·2020·Postgraduate Medical Journal

DOI 10.1136/postgradmedj-2019-137186PMC PMC7042958

Open this paper in CoChat — free account Open PDF

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia. Additionally, seven cardiovascular outcomes trials (CVOTs) have been performed in the past 4 years using lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide and oral semaglutide. All have found non-inferiority for cardiovascular outcomes, with many finding superiority of these drugs. These findings have transformed our guidelines on pharmacological treatment of T2D. This review article will discuss GLP-1 RA therapy, review the seven CVOTs reported to date and discuss the implications on current guidelines and therapies going forward.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/postgradmedj-2019-137186

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“InTroduCTIon It was first reported in 1964 that there was greater and more sustained insulin release in response to an oral glucose load when compared with the same glucose load given intravenously.(1) With the discovery of an incretin hormone known as glucosedependent insulinotropic polypeptide (GIP), this enhanced r…”
Background
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“With the discovery of an incretin hormone known as glucosedependent insulinotropic polypeptide (GIP), this enhanced release of insulin in response to ingestion of glucose became known as the ‘incretin effect’.(2) In 1986, Nauck et al showed that despite similar levels of GIP in response to an oral glucose load, patien…”
Background
2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162

Show all 26 references

Research works printed but not linked: 1

Food and Drug Administration, 2008, Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes

Sorted by citations

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 470
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
Liu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Wright, A. K., Carr, M., Kontopantelis, E., Leelarathna, L., Thabit, H., Emsley, R., Buchan, I. E., Mamas, M. A., van Staa, T. P., Sattar, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1113 · Cited by 172
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“This finding is notable given the demonstration from large scale cardiovascular outcomes trials that GLP-1R agonism is largely cardioprotective [72], and preclinical data that tachycardia observed with GLP-1R agonists dissipates over time or is minimized in the clinic with dose escalation [73,74].”
Background
2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 197
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Mu, Y., Bao, X., Eliaschewitz, F. G., Hansen, M. R., Kim, B. T., Koroleva, A., Ma, R. C. W., Yang, T., Zu, N., & Liu, M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00388-1 · Cited by 133
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 118
GLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk
Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
Pechenov, S., Revell, J. D., Will, S., Naylor, J., Tyagi, P., Patel, C., Liang, L., Tseng, L., Huang, Y., Rosenbaum, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01750-0 · Cited by 84
Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals
Kim, J. C., Park, E. J., & Na, D. H. (2022) · Pharmaceuticals · doi:10.3390/ph15121585 · Cited by 83
Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA
Shin, H., Schneeweiß, S., Glynn, R. J., & Patorno, E. (2021) · Diabetes Care · doi:10.2337/dc20-2926 · Cited by 75
The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial
Nguyen, T. N., Harris, K., Woodward, M., Chalmers, J., Cooper, M., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2664 · Cited by 72
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 76
Neuroendocrine and Metabolic Effects of Low-Calorie and Non-Calorie Sweeteners
Moriconi, E., Feraco, A., Marzolla, V., Infante, M., Lombardo, M., Fabbri, A., & Caprio, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00444 · Cited by 77
New Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 72
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Rizvi, A. A., & Rizzo, M. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s351982 · Cited by 73
Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis
Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 78
Do patients benefit from omega-3 fatty acids?
Sherratt, S. C. R., Mason, R. P., Libby, P., Steg, P. G., & Bhatt, D. L. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad188 · Cited by 75
Diabetes Mellitus and Heart Failure
Triposkiadis, F. K., Xanthopoulos, A. V., Bargiota, Α., Kitai, T., Katsiki, N., Farmakis, D. T., Skoularigis, J. S., Starling, R. C., & Iliodromitis, E. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163682 · Cited by 73
Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes
Aschen, S. Z., Zhang, A., O’Connell, G. M., Salingaros, S., Andy, C., Rohde, C. H., & Spector, J. A. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006614 · Cited by 63
Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C. L. B., Li, J., Yang, D.-Y. D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 55
Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
Stewart, J., Addy, K., Campbell, S., & Wilkinson, P. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020949326 · Cited by 68
Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)
Latif, W. A., Lambrinos, K. J., & Rodríguez, R. (2021) · StatPearls · Cited by 47
Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance
Jain, A., Ali, A., Martínez, J. J. G., HRAMIAK, I. M., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 49
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
Radkhah, H., Anaraki, S. R., Roudsari, P. P., Bahri, R. A., Zooravar, D., Asgarian, S., Dolama, R. H., Alirezaei, A., & Khalooeifard, R. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01720-9 · Cited by 60
Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials
McCullough, P. A., Amin, A., Pantalone, K. M., & Ronco, C. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024139 · Cited by 44
Mitochondrial Effects of Common Cardiovascular Medications: The Good, the Bad and the Mixed
Bețiu, A. M., Noveanu, L., Hâncu, I. M., Lascu, A., Petrescu, L., Maack, C., Elmér, E., & Muntean, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113653 · Cited by 41
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
von Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 41
Life’s Essential 8
Kumar, M., Orkaby, A. R., Tighe, C. A., Villareal, D. T., Billingsley, H., Nanna, M. G., Kwak, M. J., Rohant, N., Patel, S., Goyal, P., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100560 · Cited by 46
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
Moon, S., Lee, J., Chung, H. S., Kim, Y. J., Yu, J. M., Yu, S. H., & Oh, C.-M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.934 · Cited by 38
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
Havranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 45
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 41
Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 40
Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
Hropot, T., Herman, R., Janez, A., Lezaic, L., & Jensterle, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108592 · Cited by 39
Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms
Ahmadi, A., Panahi, Y., Johnston, T. P., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105819 · Cited by 36
Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review
Lisco, G., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., & Triggiani, V. (2020) · Endocrine · doi:10.1007/s12020-020-02444-9 · Cited by 37
The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
Stachteas, P., Karakasis, P., Patoulias, D., Clemenza, F., Fragakis, N., & Rizzo, M. (2023) · Annals of Medicine · doi:10.1080/07853890.2024.2304667 · Cited by 35
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
Rea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 32
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory
Piechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., & Kabłak-Ziembicka, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051508 · Cited by 29
Treatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 28
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
Lee, J., Hong, S., Kim, M., Moon, S. J., Kwon, H., Park, S. E., Rhee, E., & Lee, W. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0363 · Cited by 25
Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02840-3 · Cited by 27
GLP-1 (Glucagon-Like Peptide-1) Is Physiologically Relevant for Chylomicron Secretion Beyond Its Known Pharmacological Role
Nahmias, A., Stahel, P., Tian, L., Xiao, C., & Lewis, G. F. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316311 · Cited by 23
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry
Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 23
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 30
Multi-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks
Stahel, P., Xiao, C., Nahmias, A., Tian, L., & Lewis, G. F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab008 · Cited by 24
Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study ( OFFSET )
Evans, M., Chandramouli, A. S., Faurby, M. D., Matthiessen, K. S., Mogensen, P. B., & Verma, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14703 · Cited by 20
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 26
Glucagon-Like Peptide-1 Agonists
Stanton, E. W., Manasyan, A., Banerjee, R., Hong, K. M., Koesters, E. C., & Daar, D. A. (2024) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000004089 · Cited by 21
Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis
Janjusevic, M., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Sorrentino, A., Beltrami, A. P., Sinagra, G., & Aleksova, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042336 · Cited by 21
Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
Mehta, R., Billings, L. K., Liebl, A., & Vilsbøll, T. (2022) · Diabetic Medicine · doi:10.1111/dme.14901 · Cited by 18
Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study
Bepo, L., Nguyen, O. K., & Makam, A. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08961-x · Cited by 20
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 20
To tackle diabetes, science and health systems must take into account social context
Seiglie, J. A., Nambiar, D., Beran, D., & Miranda, J. J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01231-x · Cited by 17
Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals
Wang, Y., Cai, F., Li, G., & Tao, Y. (2022) · Bioengineered · doi:10.1080/21655979.2022.2051859 · Cited by 17
GLP-1R agonists: recent advances, current gaps, and future challenges
Saran, A., Raisinghani, R., Paliwal, S., & Sharma, S. K. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11195-6 · Cited by 17
Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
Basile, P., Guaricci, A. I., Piazzolla, G., Volpe, S., Vozza, A., Benedetto, M., Carella, M. C., Santoro, D., Monitillo, F., Baggiano, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041586 · Cited by 16
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 18
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Kim, J. S., Lee, G., Park, K., & Oh, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0421 · Cited by 16
Global burden, trends and inequalities for ischaemic heart disease attributable to high fasting plasma glucose, high low‐density lipoprotein cholesterol and high systolic blood pressure, 1990–2021: An analysis of the Global Burden of Disease Study 2021
An, J., Jia, Y., Shi, X., He, X., Zhang, J., Ren, Y., & He, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16199 · Cited by 15
Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis
SABOURET, P., BOCCHINO, P. P., ANGELINI, F., D’ASCENZO, F., GALATI, G., FYSEKIDIS, M., DE FERRARI, G. M., FISCHMAN, D. L., BHATT, D. L., & BIONDI-ZOCCAI, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05900-2 · Cited by 14
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 14
Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China
McEwan, P. C., Baker‐Knight, J., Ásbjörnsdóttir, B., Yi, Y., Fox, A., & Wyn, R. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01470-w · Cited by 14
A versatile bioelectronic interface programmed for hormone sensing
Ray, P. G., Maity, D., Huang, J., Zulewski, H., & Fussenegger, M. (2023) · Nature Communications · doi:10.1038/s41467-023-39015-1 · Cited by 13
The Perfect Cup? Coffee-Derived Polyphenols and Their Roles in Mitigating Factors Affecting Type 2 Diabetes Pathogenesis
Chapple, B. E., Woodfin, S., & Moore, W. (2024) · Molecules · doi:10.3390/molecules29040751 · Cited by 14
The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms
Barraclough, J., Patel, S., Yu, J., Neal, B. C., & Arnott, C. G. (2021) · Cells · doi:10.3390/cells10102699 · Cited by 13
Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
Widiarti, W., Sukmajaya, A. C., Nugraha, D., & Alkaff, F. F. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.005 · Cited by 13
GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models
Zhang, M., Zhang, Y., Peng, X., He, A., Wang, Y., Deng, Y., Cui, C., Xue, F., Wei, B., Xing, W., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175107 · Cited by 12
Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration
Wilhite, K., Reid, J. M., & Lane, M. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280231205490 · Cited by 12
Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury
Ismaeil, A., Babiker, F. A., & Al‐Sabah, S. (2022) · Pharmaceuticals · doi:10.3390/ph15060720 · Cited by 12
Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus
Wong, E., Cope, R. J., Dima, L., & Nguyen, T. K. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001588 · Cited by 13
Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment
Lohia, S., Siwy, J., Mavrogeorgis, E., Eder, S., Thöni, S., Mayer, G. J., Mischak, H., Vlahou, A., & Jankowski, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713540 · Cited by 11
Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 12
The relation between excess adiposity and breast cancer in women: Clinical implications and management
Hurtado, M. D., Tama, E., D’Andre, S., & SHUFELT, C. L. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104213 · Cited by 11
Primary prevention of cardiovascular disease in women
Gray, M. P., Vogel, B., Mehran, R., Leopold, J. A., & Figtree, G. A. (2024) · Climacteric · doi:10.1080/13697137.2023.2282685 · Cited by 11
Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)
Oe, Y., Nomoto, H., Cho, K. Y., Yokozeki, K., Ono, T., Miya, A., Kameda, H., Nakamura, A., Arimura, Y., & Atsumi, T. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01658-6 · Cited by 10
Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis
Alfehaid, L., Yami, M. S. A., Almohareb, S. N., Alshaya, O. A., & Almutairi, A. R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2465870 · Cited by 10
Protective effect of glucagon-like peptide-1 mediated by ultrasound microbubbles on myocardial injury in rats with diabetic cardiomyopathy
Liu, Y., Chen, L., Wu, H., & Zhang, H. (2022) · Bioengineered · doi:10.1080/21655979.2021.2022270 · Cited by 10
Insulin Therapy is Associated With Increased Myocardial Interstitial Fibrosis and Cardiomyocyte Apoptosis in a Rodent Model of Experimental Diabetes
Adel, F., Ye, Z., Wan, S., Greason, C. M., Pan, S., Ameenuddin, S., & Chen, H. H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.890907 · Cited by 10
GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?
Stoll, L., & Lo, J. C. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.03.022 · Cited by 10
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
Lee, B., Cho, Y. M., Kim, S. G., Ko, S., Lim, S. K., Dahaoui, A., Jeong, J. S., Lim, H. J., & Yu, J. M. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01515-0 · Cited by 12
Do anti-obesity medical treatments have a direct effect on adipose tissue?
Vergès, B. L. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.05.021 · Cited by 9
Ultrasound-targeted semaglutide-loaded PEG-nanoliposomes microbubble destruction protects diabetic cardiomyopathy by activating PI3K/Akt/Nrf2 signaling pathway
Zhu, J., Wang, H., Yan, C., Li, B., & Chen, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19873 · Cited by 9
Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use
DAGHER, C., Jailani, M., Akiki, M., Siddique, T., Saleh, Z., & Nadler, E. (2024) · Cureus · doi:10.7759/cureus.69704 · Cited by 8
A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study
Romera, I., Artime, E., Ihle, K., Díaz‐Cerezo, S., Santos, M. R., Prado, A. D., Cuenca, A. M. C., & Conget, I. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02196-0 · Cited by 7
Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 8
GLP1 agonists beyond glycemic control—redefining their role
Chowdhury, S., & Goswami, S. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00879-4 · Cited by 7
The crucial relationship between miRNA-27 and CSE/H 2 S, and the mechanism of action of GLP-1 in myocardial hypertrophy
Gao, S., Li, Y., Liu, M.-M., Xiong, X., Cui, C.-P., Huo, Q., Li, K., Sun, X., Zhang, R., Wu, D., et al. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.93720 · Cited by 6
Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
Han, J., Lee, W. J., Hur, K. Y., Cho, J., Lee, B., & Park, C. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0030 · Cited by 6
Semaglutide sustained-release microspheres with single-phase zero-order release behavior: Effects of polymer blending and surfactants
Jiang, W., Wang, Q., Zhang, X., Yang, H., & Yang, X. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106793 · Cited by 6
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 6
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
Salmen, T., BOBIRCA, F. T., Bica, I.-C., Mihai, D. A., Pop, C. S., & Stoian, A. P. (2023) · Life · doi:10.3390/life13030839 · Cited by 8

Authors: Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P.
Affiliations: University of Vermont Medical Center (US)
Corresponding author: Sheahan, Kelsey H
ORCID: Sheahan, Kelsey H
Wahlberg, Elizabeth A
Gilbert, Matthew P
Venue: Postgraduate Medical Journal
Publisher: Oxford University Press (OUP)
Published: 2019-12-04
Volume: 96
Issue: 1133
Pages: 156-161
ISSN: 0032-5473 (ISSN-L)
1469-0756
DOI: 10.1136/postgradmedj-2019-137186
PMC: PMC7042958
OpenAlex: W2992144798
Cited by: 194
References: 26
Citations by year: 2026: 10 · 2025: 28 · 2024: 31 · 2023: 27 · 2022: 43 · 2021: 47 · 2020: 8
FWCI: 19.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0/ (vor, 1131 d)
creativecommons.org/licenses/by-nc/4.0/ (unspecified)
Locations: Postgraduate Medical Journal (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
HighWire Press Open Archive (submittedVersion)
Funders: Sanofi
Max-Planck-Gesellschaft
Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: GLP-1 receptor agonists, type 2 diabetes, lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide, oral semaglutide, HbA1c, weight loss, hypoglycemia, treatment guidelines
MeSH terms: Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Medication Therapy Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks